. In the present study, the AR subdomains involved in this in vivo interaction were determined in more detail. Cotransfection experiments in Chinese hamster ovary (CHO) cells and two-hybrid experiments in yeast revealed that two regions in the NH 2 -terminal domain are involved in the functional interaction with the LBD: an interacting domain at the very NH 2 terminus, located between amino acid residues 3 and 36, and a second domain, essential for transactivation, located between residues 370 and 494. Substitution of glutamic acid by glutamine at position 888 (E888Q) in the AF-2 activation domain (AD) core region in the LBD, markedly decreased the interaction with the NH 2 -terminal domain. This mutation neither influenced hormone binding nor LBD homodimerization, suggesting a role of the AF-2 AD core region in the functional interaction between the NH 2 -terminal domain and the LBD. The AF-2 AD core region was also involved in the interaction with the coactivator TIF2 (transcriptional intermediary factor 2), as the E888Q mutation decreased the stimulatory effect of TIF2 on AR AF-2 activity. Cotransfection of TIF2 and the AR NH 2 -terminal domain expression vectors did not result in synergy between both factors in the induction of AR AF-2 activity. TIF2 highly induced AR AF-2 activity on a complex promoter [mouse mammary tumor virus (MMTV)], but it was hardly active on a minimal promoter (GRE-TATA). In contrast, the AR NH 2 -terminal domain induced AR AF-2 activity on both promoter constructs. These data indicate that both the AR NH 2 -terminal domain and the coactivator TIF2 functionally interact, either directly or indirectly, with the AF-2 AD core region in the AR-LBD, but the level of transcriptional response induced by TIF2 depends on the promoter context.
INTRODUCTION
The human androgen receptor (hAR) mediates physiological effects of testosterone and dihydrotestosterone (DHT), which are essential for development and functional maintenance of male reproductive and accessory sex tissues. As a ligand-dependent transcription factor, its structural organization shows a high level of molecular identity to other members of the nuclear receptor superfamily. For these receptors, separate functional domains have been characterized. The variable NH 2 -terminal domain is involved in transcription activation and contains the transactivation function AF-1 (see Ref. 1 for review). The centrally located, highly conserved DNA-binding domain (DBD) mediates the interaction with hormone-response elements on the DNA (2) . The carboxy-terminal (C-terminal) region contains the ligand binding domain (LBD), which is involved in receptor dimerization (3) (4) (5) (6) , and can functionally interact with transcriptional intermediary factors (TIFs) (for review see Ref. 7) .
For the hAR, two separate transcription activation units (TAUs) in the NH 2 -terminal domain were defined (8) . One of these transactivation units [TAU-1; amino acids (aa) 100-370] is only active in the full-length ligand-activated AR. In a truncated hAR, which lacks the LBD, another region (TAU-5, aa 360-485) functions as a constitutively active transactivation domain. The role of TAU-5 in the full-length AR is not yet clear.
The LBDs of various nuclear receptors contain a ligand-dependent transactivation function, AF-2 (9) (10) (11) . An autonomous activating domain (AD) in this AF-2 region, AF-2 AD, is conserved among many nuclear receptors and is located in the C-terminal part of the LBD. A core region in the AF-2 AD, ␣-helix 12, appeared to be important for transcriptional activity (9, 10, 12, 13) and the hormone-dependent interaction with TIFs. These TIFs or coactivators can modulate the transcriptional activity of a broad range of nuclear receptors (14) (15) (16) (17) . Mutations in the AF-2 AD core abolish the in vitro association of the receptor with these coactivators. The recent finding that a coactivator displays histone acetyltransferase activity has provided further insights into the molecular events occurring at the chromatin level during transcription activation (18) . Wurtz et al. (19) proposed a general mechanism for nuclear receptor activation, in which the AF-2 AD core, present in helix 12, plays a central role in the generation of an interaction surface, allowing binding of TIFs to the LBD. The functional role of the AF-2 AD core in the AR is not yet well understood.
Recently, for the estrogen receptor (ER) a functional, ligand-dependent, in vivo association between the NH 2 -terminal domain and the LBD was described (20) . Also for the AR a functional in vivo interaction between the NH 2 -terminal domain and the LBD was demonstrated (21, 22) . In the study presented here, we determined in more detail AR subdomains involved in the functional interaction of the LBD with the NH 2 -terminal domain. The data indicated that two NH 2 -terminal regions, together with the AF-2 AD core region in the LBD, are important for a functional in vivo interaction. Induction of AR AF-2 activity by the transcriptional coactivator TIF2 also required an intact AF-2 AD core. This enhancement of AR AF-2 activity by TIF2 appeared to be promoter dependent.
RESULTS

Two Regions in the AR NH 2 -Terminal Domain Are Involved in the Functional Interaction with the AR-LBD
Studies in CHO Cells A functional in vivo association between the NH 2 -terminal domain and LBD of the hAR was found previously (22) . Experiments performed in yeast and mammalian cells showed that this interaction was hormone dependent and could be blocked by antiandrogens. The present study focused on AR subdomains involved in this NH 2 -terminal domain/LBD protein-protein interaction.
To determine regions in the NH 2 -terminal domain involved in the functional interaction with the AR-LBD, different deletion mutants of the NH 2 -terminal domain were constructed, as shown in Fig. 1A (AR.N1-AR.N7). The deletion mutants were transiently transfected into CHO cells, and the appropriate expression of the proteins was assessed by immunoaffinity purification and Western blot analysis of cytosolic fractions (Fig. 1B,  lanes 1-7) . Constructs (AR.N1-AR.N6) were expressed as proteins of expected molecular mass and at comparable expression levels. The expression level of AR.N7 could not be determined because this protein lacks an epitope for the available antibodies. The ability of these mutants to induce transcription activation through interaction with the AR-LBD ( Fig.  1A ; AR.C), using mouse mammary tumor virus (MMTV)-LUC as a reporter gene, is shown in Fig. 2 . As shown previously (22) , neither AR.N1 nor AR.C could, when expressed separately in CHO cells, activate transcription from the reporter in response to androgens. The lack of activity of AR.C is not due to the experimental setup, because a similar glucocorticoid receptor (GR) fragment, GR.C (aa 369-777), highly induced luciferase activity in CHO cells (24-fold) upon addition of 10 nM dexamethasone (data not shown). Coexpression of AR.N1 and AR.C resulted in an androgen-dependent induction (18-fold) of luciferase expression ( Fig. 2 ; AR.N1), which is comparable to fulllength AR activity. Deletion mutants AR.N2 and AR.N3 showed similar responses as seen with the intact NH 2 -terminal domain. However, deletion of amino acid residues 371-494 markedly reduced the androgeninduced LUC-activity (AR.N4). Deletions in the first part of the NH 2 -terminal domain (AR.N5, AR.N6, AR.N7) almost completely abolished the R1881-mediated response. These data indicate that, for a functional interaction of the NH 2 -terminal domain with the LBD of the AR in CHO cells, amino acid residues 1-51 and 371-494 are important. This suggests that the TAU-5 domain, located in the latter region, is involved in this functional in vivo interaction. The region between residues 51 and 360, harboring TAU-1, appears not to be involved.
Studies in Yeast
To extend the CHO cell experiments, functional NH 2 -terminal domain/LBD interactions were studied in yeast, using a two-hybrid system. The high sensitivity of the yeast two-hybrid assay made it also possible to detect weak associations. Furthermore, because of the presence of the Gal4 transactivation domain, the in vivo interaction does not solely depend on an intact AR-transactivating domain.
Truncated forms of the AR NH 2 -terminal domain were fused to the transactivation domain of GAL4 (Gal4-TAD), in the high-expression vector pACT2 (Fig.  3A) . AR-LBD was fused to the DBD of GAL4 (Gal4-DBD). Figure 3B shows the protein expression in yeast Y190 cells, as assessed by immunoblot analysis using specific antibodies directed against either the AR (lanes 1-4) or Gal4-TAD (lanes 5-10). The immunoblot shows expression of most fusion proteins of the appropriate length. However, the expression of GalAD-AR.N9 (lane 2) appeared to be somewhat lower. GalAD-AR.N8 became visible only at an extended exposure time (lane 1a), indicating a very low protein expression level.
Activation of the integrated UAS GAL1 -lacZ reporter gene, indicative for the functional interaction of GalAD-AR.N with the promoter-bound GalDBD-AR.C, was assessed in a ␤-galactosidase (␤-GAL) assay (Fig. 4A) . The observed reporter gene activity for GalAD-AR.N8 was lower as compared with GalAD-AR.N9, GalAD-AR.N10, and GalAD-AR.N12, most likely due to the very low protein expression level of GalAD-AR.N8. The constructs showing a high ␤-GAL activity (GalAD-AR.N8, -N9, -N10, and -N12) all share one common region, spanning residues 3-36. Deletion of this region from constructs GalAD-AR.N12 and GalAD-AR.N15, resulting in constructs GalAD-AR.N13 and GalAD-AR.N16, respectively, caused an intense drop in ␤-GAL activity. Therefore, in accordance with the CHO results, the data imply an important role of NH 2 -terminal amino acid residues 3-36 in the functional interaction with the AR-LBD.
Mutant GalAD-AR.N11, missing residues 245-494, was reduced in its activity as compared with the intact NH 2 -terminal domain. A decrease in activity was also seen when residues 330-494 were deleted from GalAD-AR.N12, resulting in GalAD-AR.N15. This implies that a second region, between residues 244 and 494, is involved in the functional interaction with the LBD. More detailed mapping within this region did not clearly reveal distinctive interaction sites, because neither deletion of residues 245-360 (GalAD-AR.N9), nor deletion of residues 371-494 (GalAD-AR.N10), resulted in a distinct decrease of ␤-GAL activity. However, interpretation of these data is complicated because of the difference in expression levels of the different constructs (Fig. 3B) .
As reported previously (22) , the measured ␤-GAL activities are partly due to Gal4-TAD transactivity, but could also be influenced by the intrinsic transactivating activity of the AR NH 2 -terminal domain. The contribution of the intrinsic AR activity to the total measured ␤-GAL activity could vary between different constructs and thereby affect the mapping of interacting regions. To discriminate between AR transactivity and AR interaction potential, the Gal4-TAD part was deleted from these GalAD-AR.N constructs that showed a considerable interaction with GalDBD-AR.C (as depicted in Fig. 4A ). This resulted in constructs AR.N8-AR.N12 and AR.N15. Protein expression of these constructs, as determined by immunoblot analysis, is shown in Fig. 3B (lanes 11-16) .
The activities of the AR.N constructs, in the twohybrid assay with GalDBD-AR.C, are shown in Fig. 4B .
AR.N11 and AR.N15 did not induce a functional interaction, although the corresponding Gal4-TAD chimeric constructs, as shown in Fig. 4A , were active. This indicates that AR.N11 and AR.N15 only contain interaction potential and not transactivity. These constructs have the 3-36 fragment in common. Deletion of the region between residues 244 and 360 (AR.N9) did not reduce ␤-GAL activity; AR.N12 (missing residues 37-243) also showed a clear response. This indicates that both these proteins still have transactivating activity and interaction potential. However, by deleting residues 371-494 (AR.N10), ␤-GAL activity dropped by approximately 80%, a decrease comparable to the data obtained in CHO cells ( Fig. 2 ; AR.N4). These results narrow the second interacting region (aa 244-494) to involvement of residues 371-494 as a major transactivation domain in the functional interaction with the LBD.
Taken together, the yeast two-hybrid data imply a prominent role of amino acid residues 3-36 of the AR NH 2 -terminal domain in the interaction with the LBD. A second region seems to be mainly constrained to residues 371-494 and further supports the involvement of TAU-5, as a transactivating region, in the functional in vivo interaction with the LBD.
A Mutation in the LBD Affects the Functional Interaction with the NH 2 -Terminal Domain, but not LBD Dimerization
To determine regions in the AR-LBD involved in the functional interaction with the NH 2 -terminal domain, mutational analysis was constrained to the conserved amphipathic helix 12 in the LBD. This helix constitutes the AF-2 activation domain (AD) core region, of which the charged residues might generate a protein-protein interacting surface (19) . A single amino acid substitution in the AF-2 AD core was introduced: glutamic acid at position 888, which is highly conserved among nuclear receptors, was replaced by glutamine (E888Q).
Both the wild-type and the mutated LBD construct ( Fig. 1A ; AR.C and AR.C(EQ), respectively) were transfected into CHO cells. The appropriate expression of both proteins is shown in Fig. 1B (lanes 8 and 9) . To determine whether the AF-2 AD mutation had an effect on hormone binding, an in vivo androgen binding assay in transfected CHO cells was performed. Scatchard analysis of the data revealed that both proteins had similar K d values for R1881: AR.C, 0.37 nM, and AR.C(EQ), 0.33 nM, respectively, indicating that the E888Q mutation did not affect hormone binding.
The effect of the E888Q mutation on the functional in vivo interaction of the LBD with the NH 2 -terminal domain was investigated by cotransfecting AR.N1 with increasing amounts of either AR.C or AR.C(EQ) and the MMTV-LUC reporter into CHO cells (Fig. 5A ). As expected, no response to 1 nM R1881 was observed in the absence of the LBD constructs. Coexpression of AR.C and AR.N1 resulted in a high induction (to 24-fold) of luciferase activity. The E888Q mutation Luciferase activity was determined as described in Materials and Methods. The interexperimental variation of the mean maximal luciferase activities ranged between 2,000 and 9,000 light units. For each experiment the mean AR.N1 activity was set at 100%, and all individual points were calculated relative to this value. Each bar represents the mean (Ϯ SEM) luciferase activity for three experiments. Fold induction is shown at the top of each bar and represents the ratio of activity determined in the presence or absence of R1881.
Interaction of hAR AF-2 with NH 2 Terminus and TIF2strongly reduced the response to R1881 (to maximally a 7-fold induction) as compared with the wild-type LBD.
The effect of the E888Q mutation on the functional interaction between the two AR domains was also studied in yeast, using the two-hybrid system. Both C-terminal domains (wild-type and mutant), fused to Gal4-DBD, were transformed together with GalAD-AR.N8 into Y190 ( Fig. 5B ; NH 2 /LBD). The effect of the E888Q mutation appeared to be even more pronounced than in CHO cells, as ␤-GAL activity measured for the interaction of both AR domains (set at 100% for the intact LBD) dropped more than 90% upon introduction of the E888Q mutation. The data from CHO cells and from yeast indicate that the AF-2 AD core region in the AR-LBD is important for a functional interaction with the NH 2 -terminal domain.
Previously, homodimerization of the AR-LBD was demonstrated in yeast (22, 23) . To determine whether the E888Q mutation had an effect on LBD dimerization, both LBDs (wild-type and mutant) were coupled to Gal4-TAD and transformed together with the corresponding LBD domains coupled to Gal4-DBD (Fig.  5C ). In this LBD/LBD interaction assay, the wild-type AR.C and the mutant AR.C(EQ) showed similar ␤-GAL levels, indicating that the E888Q mutation had no effect on LBD dimerization. 
TIF2-Induced Activity of AR AF-2 in CHO Cells Is Affected by the E888Q Mutation
The functional role of the AR AF-2 AD core region was further characterized by comparing the functional in vivo interaction of the AR-LBD and the AR NH 2 -terminal domain with the interaction of the AR-LBD and the coactivator TIF2. The coactivator TIF2 is able to enhance the AF-2 activity of several steroid receptors including the AR (17) . The involvement of the AR AF-2 AD core region in the functional in vivo interaction of TIF2 and the AR-LBD was investigated by examining the effect of the E888Q mutation. TIF2 was cotransfected with the MMTV-LUC reporter and increasing amounts of the wild-type (AR.C) or the mutant LBD (AR.C(EQ)) into CHO cells (Fig. 6 ). In the absence of the LBD constructs, no response to 1 nM R1881 was observed. As expected, coexpression of TIF2 and AR.C highly induced luciferase activity (up to 26-fold). The E888Q mutation reduced luciferase activity by approximately 70%, compared with AR.C. This decrease in functional interaction of AR-LBD with TIF2, caused by the E888Q mutation, was comparable to the negative effect of the mutation on the interaction with the NH 2 -terminal domain (as shown in Fig. 5A ).
TIF2 Does Not Promote the Functional Interaction between the AR NH 2 -Terminal Domain and the LBD
To determine whether TIF2 enhances the functional interaction between the NH 2 -terminal and C-terminal domains of the AR, coexpression studies with different concentrations of TIF2 and the NH 2 -terminal domain were performed (Fig. 7) . The luciferase activities obtained were compared with the transactivating activities measured after separate transfection of the different plasmids. Individual expression of TIF2 and the NH 2 -terminal domain induced the transcriptional activity of AR.C on the MMTV promoter up to 24-fold (panels a and d, respectively). When coexpressed with 50 ng/well AR.N1 (panel b), TIF2 slightly enhanced the luciferase activity induced by the functional interaction of AR.N1 and AR.C (up to 34-fold). When higher amounts of AR.N1 were transfected, no additional effects of TIF2 could be observed (panels c and d). These data most likely exclude synergy between TIF2 and the NH 2 -terminal domain for the interaction with the AR-LBD, indicating that TIF2 is not necessary for the functional interaction between the AR domains.
TIF2-Induced Activity of AR AF-2 in CHO Cells Is Promoter Dependent
To further examine the induction of AR AF-2 activity by the NH 2 -terminal domain and by TIF2, in vivo interaction assays in CHO cells were performed using different promoter constructs (Fig. 8) . AR.C was cotransfected into CHO cells with increasing amounts of either AR.N1 (Fig. 8, A and C) or TIF2 (Fig. 8, B and D) , together with either MMTV-LUC (Fig. 8, A and B) or GRE-TATA-LUC (Fig. 8, C and D) as reporter constructs. In the absence of either AR.N1 or TIF2, no significant response to 1 nM R1881 could be detected. AR.N1 as well as TIF2 induced AF-2 activity on the MMTV-LUC promoter (maximally 39-and 44-fold, respectively). Luciferase activity was also highly induced by AR N.1 on the minimal, GRE-TATA, promoter (Fig.  8C) . In contrast, the TIF2-induced luciferase activity appeared to be much more affected on this promoter (Fig. 8D ). This indicates that the level of transcriptional 
DISCUSSION
Upon hormone binding, steroid receptors undergo conformational changes that result in a cascade of events leading toward DNA binding and transcription activation. Protein-protein interactions play a prominent role in these processes. After releasing associated heatshock proteins, the receptor homodimerizes, and subsequently interacts with TIFs and basal transcription factors, to induce transcription of specific target genes (3-7). For the hAR, two separate transcription activation units in the NH 2 -terminal domain were defined: TAU-1 and TAU-5 (8) . TAU-1 is active in the full-length, hormone-bound AR, whereas TAU-5 is active in a constitutive receptor that lacks the LBD. This shift in TAU in the NH 2 -terminal domain, depending on the absence or presence of the LBD, suggested a functional interaction between the LBD and the NH 2 -terminal domain.
It was described recently, for the ER and AR, that functional in vivo interactions between the separate NH 2 -terminal domain and the LBD can occur (20) (21) (22) . Whether this association is direct or requires additional factors is unknown. Neither is it clear which regions in these AR domains are involved in this functional interaction. For a better understanding of AR action, we determined the subdomains in the AR involved in the functional interaction between the NH 2 -terminal domain and the LBD.
Cotransfection experiments of the AR-LBD with NH 2 -terminal deletion mutants in CHO cells and in yeast imply a major role for amino acid residues 3-36 of the NH 2 -terminal domain in the functional in vivo interaction with the LBD. A previous report by Langley et al. (21) indicated residues 14-150 to be involved, suggesting that the interaction domain might be constrained to residues 14-36. In this respect it is interesting that region 16-36 is potentially capable of forming an amphipathic ␣-helix, if projected on a helical wheel diagram.
Experiments in CHO cells revealed a second region, amino acid residues 371-494, important for a functional in vivo interaction with the AR-LBD. The involveGalDBD-AR.C(EQ). ␤-GAL activity was determined after incubation of the cells in the absence (open bars) or presence (solid bars) of 1 M DHT. Fold induction represents the ratio of activity determined in the presence and absence of DHT. ␤-GAL values represent the mean (ϮSEM) of three experiments. C, Yeast Y190 cells, containing the integrated UASGal1 -lacZ reporter gene, were transformed with GalDBD-AR.C (low) and GalAD-AR.C (high) or GalDBD-AR.C(EQ) (low) and GalAD-AR.C(EQ) (high). ␤-GAL activity was determined as described in panel B. (24) described the interaction of the AR NH 2 -terminal domain (aa 142-485) with the general transcription factor TFIIF. It remained unclear which of the transactivation units (TAU-1 or TAU-5) in the AR NH 2 -terminal domain is involved in the interaction with TFIIF, as both TAUs are present in the AR domain used in this study. Therefore, the role of TAU-5 in the interaction with the AR-LBD might be, at least in part, by recruiting the transcriptional machinery to the target promoter.
The in vivo experiments described here imply an important role for the AR AF-2 AD core in the functional interaction with the NH 2 -terminal domain. The E888Q mutation markedly decreased the interaction between the two AR domains, without altering hormone binding. As the E888Q mutation did not completely reduce the interaction, it is likely that also other residues or regions in the LBD are involved in the formation of a proper interacting surface. Wurtz et al. (19) proposed a general mechanism for nuclear receptor activation, in which hormone-induced conformational changes within the LBD result in a close contact of helix 12 and helix 4, thereby creating an interaction surface that allows binding of coactivators to the AF-2 activation domain. As the formation of this interaction surface might also be important for the functional interaction of the LBD with the NH 2 -terminal domain, this would suggest that helix 4 is involved. Two-hybrid experiments in yeast showed that the E888Q mutation affected the functional interaction with the NH 2 -terminal domain but did not influence LBD homodimerization. This implies that different regions in the AR-LBD are involved in the interaction with the NH 2 -terminal domain and in LBD dimerization.
The E888Q mutation also decreased the stimulatory effect of the coactivator TIF2 on AR AF-2 activity. This suggests that the AF-2 AD core region of the hAR is involved in interacting with both the NH 2 -terminal domain and the coactivator TIF2. A possible mechanism of TIF2 action could be as a bridging factor in the process of transcription activation by the AR. McInerney et al. (25) demonstrated that the steroid receptor coactivator SRC-1 enhanced the functional interaction between the NH 2 -terminal and C-terminal domain of the ER. From these data it was suggested that SRC-1 may act as an adaptor protein that promotes the in- . LUC activity was determined as described in Materials and Methods. The interexperimental variation of the mean maximal luciferase activities ranged between 120,000 and 375,000 light units. For each experiment the mean AR.N1 activity (400 ng/well) was set at 100%, and all individual points were calculated relative to this value. Each bar represents the mean (ϮSEM) luciferase activity of three experiments. Fold induction represents the ratio of activity determined in the presence and absence of R1881. tegration of NH 2 -terminal and C-terminal ER domains. However, cotransfection experiments with TIF2 and the AR NH 2 -terminal domain in CHO cells did not show synergy between TIF2 and the AR NH 2 -terminal domain in the induction of AR AF-2 activity (Fig. 7) . Therefore, it is unlikely that TIF2 functions as a bridging factor for the functional interaction of the NH 2 -terminal domain and the LBD of the AR.
The AR appears to be a unique member in the nuclear receptor superfamily, because the AR Cterminal domain, containing the AF-2 AD core region, is inactive in the absence of the NH 2 -terminal domain or TIF2. This lack of activity is not due to the experimental setup or the cell type used (CHO), because a similar C-terminal construct of the GR is active. The most likely explanation of this difference is that interactions of the AR-AF2 AD with endogenous coactivators are very weak and therefore undetectable. Overexpression of coactivators (e.g. TIF2) might enhance the interaction and consequently transcriptional activity. Another explanation for the absence of AR AF-2 activity in CHO cells is that endogenous levels of TIF2 are not sufficient for activation of the MMTV promoter in the absence of AR.N1.
A signature motif in transcriptional coactivators that mediated binding to liganded nuclear receptors was described recently (26) (27) (28) . Most coactivators, including TIF2, harbor several of these leucine-rich motifs (LXXLL). Two-hybrid experiments in yeast revealed that the interaction of the ER-LBD with LXXLL motifs was abolished by mutating the AF-2 AD core region in the LBD (26) . Despite the demonstration that the NH 2 -terminal domain of the AR also interacts with the AF-2 AD, it does not harbor such a motif, suggesting a different type of cooperation between the two AR domains.
The induction of AF-2 activity by TIF2 appeared to be promoter dependent. TIF2 strongly stimulated AR AF-2 activity on a MMTV-LUC reporter but much less on a minimal GRE-TATA promoter. The AR NH 2 -terminal domain could, in contrast to TIF2, induce AF-2 activity on both promoters. Possibly, TIF2 not only affects the AR but also interacts with other transcription factors that bind to the complex MMTV promoter and not to the minimal promoter.
From the data presented here, together with previously obtained results (22) , the following model for functional interactions between AR domains is proposed. Androgen binding induces a conformational change in the receptor that facilitates the AF-2 AD core in the LBD to interact with the NH 2 -terminal domain. This interaction might be either direct or indirect, requiring additional factors, and results in AR transcription activation. Enhancement of AR activity by the coactivator TIF2 also involves the AF-2 AD core. In addition to a functional NH 2 -terminal domain/LBD interaction, a LBD/LBD interaction is proposed that requires a region different from the AF-2 AD core.
MATERIALS AND METHODS
Plasmid Construction
Plasmid constructions were performed according to standard methods (29) and where denoted, rendered blunt ended with Klenow. All blunt-ended fusion constructs, and constructs including a PCR amplification step for preparation, were sequenced to verify the correct reading frame and the absence of random mutations. AR.N1 and AR.C were described previously as pSVAR(TAD 1Ϫ494 ) (22) and pSVAR-104 (8), respectively. AR.N2, AR.N3, AR.N5, AR.N6, and AR.N7 were obtained by modification of AR ⌬ 51-211 and AR ⌬ 244-360 (30), AR124, AR127, and AR106 (8) respectively : plasmids were digested with KpnI and EcoRI and religated by a KpnI-EcoRI linker. AR.N4 was obtained by insertion of a RsrII-EcoRI linker into AR.N1. pSVAR(EQ) was constructed by site-directed mutagenesis of pSVAR (31), using the following oligonucleotides (the modified codon is shown underlined):
AR/EQ1: 5Ј-ACAGCCAGTGTGTCCGAATG-3Ј; AR/EQ2: 5Ј-CTTGCACAGAGATGATTTGTGCCATC-3Ј; AR/EQ3: 5Ј-GATGGCACAAATCATCTCTGTGCAAG-3Ј; AR/EQ4: 5Ј-CAAGGGGCTTCATGATGTCC-3Ј. AR.C(EQ) was prepared by digestion of pSVAR(EQ) with EcoRI and ligating the 465-bp fragment into AR.C. MMTV-LUC reporter plasmid was kindly provided by Dr. Dijkema (Organon, Oss, The Netherlands) and was described previously (32) . GRE-TATA-LUC, containing the TATA-box and a Sp1-site derived from the Oct-6 gene promoter, has been described previously as pJH4-(ARE) 2 -OCT-LUC (33) . GR.C (aa 369-777) was constructed by digestion of RshGR␣ (34) . LUC activity was determined as described in Materials and Methods. The interexperimental variation of the mean maximal luciferase activities ranged between 4,800 and 6,400 light units for panels A and B, and between 11,500 and 13,500 light units for panels C and D. For each experiment the mean AR.N1 activity (1000 ng/well) was set at 100%, and all individual points were calculated relative to this value. Each bar represents the mean (ϮSEM) luciferase activity of three experiments. Fold induction represents the ratio of activity determined in the presence and absence of R1881.
MOL ENDO · 1998 Vol 12 No. 8 with BstXI and religation with a compatible DNA fragment obtained by annealing the following oligos: 5Ј-AGCCCGG-GACCATGGGAT-3Ј and 5Ј-CATGGTCCCGGGCTATCC-3Ј. The obtained plasmid was digested with SmaI and DraI, and the 1074-bp fragment, containing the GR DBD and LBD, was ligated into SmaI-digested pSV328A (35) . The GAL4(DBD 1Ϫ147 ) two-hybrid cloning vector pGBT9 and the parental GAL4(TAD 768Ϫ881 ) cloning vector pGAD424 (low expression), or the high-level expression derivative pACT2 (all from Clontech, Palo Alto, CA), were used to generate all yeast fusion protein constructs. GalAD-AR.N8 (low) was described previously as pGAL4(TAD)AR(TAD) (22) . GalAD-AR.N11 (low) was generated by digesting GalAD-AR.N8 (low) with NcoI and SalI, followed by religation of the blunted vector. The previously described pTZ19NAR (22) , containing an additional BamHI site by addition of a BamHI linker to the blunt-ended EcoRI site in the polylinker, was digested with SmaI and NcoI, and the resulting vector was blunt ended and religated, yielding pTZ19AR.N12. The AR fragment was excised with BamHI and cloned in frame into the corresponding site in pGAD424, yielding GalAD-AR.N12 (low). The 0.4-kb EcoRI-Acc651 (blunt ended) fragment from the previously described pSVAR-123 (8), containing an additional EcoRI site by addition of an EcoRI linker to the blunt-ended XbaI site, was cloned in frame into pGAD424 via EcoRI and SmaI compatible ends, yielding GalAD-AR.N14 (low). GalDBD-AR.N8 (low) [previously described as pGAL4(DBD)-AR(TAD) (22) ] was digested with RsrII and Acc651, and the blunted vector was religated, yielding GalDBD-AR.N10 (low). The AR fragment was excised with BamHI and cloned in frame into the corresponding site in pGAD424, yielding GalAD-AR.N10 (low). GalAD-AR.N15 (low) was generated by deletion of the internal PstI fragment from GalAD-AR.N12 (low). GalAD-AR.N16 (low) was constructed by digesting GalAD-AR.N15 (low) with EcoRI and NcoI, followed by religation of the blunted vector. GalAD-AR.N13 (low) was prepared by integration of the 0.5-kb GalAD-AR.N12 (low) PstI fragment into the homologous GalAD-AR.N16 (low) site. AR.N8, containing the AR fragment cloned in frame to the SV40 large T antigen nuclear localization signal in pGAD424, was described previously as pAR(TAD 3Ϫ494 ) (22) . AR.N12 (low) was generated by exchanging the Acc651 (blunt ended)-EcoRI fragment of pGAD424 with the 0.9-kb BamHI (blunt ended)-EcoRI fragment of pTZ19AR.N12. AR.N15 (low) was prepared by digesting GalAD-AR.N15 (low) with Acc651 and BamHI, followed by religation of the blunt-ended vector. All high expression derivatives were constructed by exchanging the internal HindIII fragments with the internal pACT2 HindIII fragment. AR.N9 (high) was generated by exchanging the internal 0.9-kb StuI-EcoRI fragment of AR.N8 (high) with the 0.5-kb StuI-EcoRI fragment of AR.N3 (described above). AR.N11 (high) was generated by digesting AR.N8 (high) with NcoI and EcoRI, followed by religation of the blunt-ended vector. Similarly, the high expression level AR.N10 was generated by digesting AR.N8 (high) with RsrII and EcoRI, followed by religation of the blunt-ended vector. Only the high expression AR.N constructs were used in the two-hybrid assays. The expression vectors GalDBD-AR.C (low expression) and GalAD-AR.C (high expression) were previously described as pGAL4(DBD)AR(LBD) and pGAL4(TAD)AR(LBD), respectively (22) . GalDBD-AR.C(EQ) was prepared by integration of the 0.7-kb StuI-SalI fragment of pSVAR(EQ) (as described above) into the homologous GalDBD-AR.C sites. Similarly, the high-expression GalAD-AR.C(EQ) derivative was generated by integration of the 0.45-kb EcoRI fragment of pSVAR(EQ) into the homologous GalAD-AR.C site.
CHO Cell Culture, Transfection, and LUC Assay
Chinese hamster ovary (CHO) cells were maintained in DMEM/F12 culture medium, supplemented with 5% dextrancoated charcoal-treated FCS (Life Technologies, Gaithersburg, MD). For transcription activation experiments, CHO cells were plated in 12-well plates at a density of 0.6 ϫ 10 5 cells per well (7 cm 2 ) and grown overnight. Cells were transfected using the calcium phosphate precipitation method as described previously (36) , with AR expression plasmids and where indicated with TIF2, reporter plasmids (200 ng/well), and pTZ19 carrier plasmid to a total DNA concentration of 2 g/well. After an overnight incubation, the cells were washed and R1881 (methyltrienolone; New England Nuclear, Boston, MA) or vehicle (0.1% ethanol) was added. After overnight incubation the cells were harvested for the luciferase (LUC) assay, as described previously (37) . For the GR experiments, GR.C (50 ng/well) was cotransfected with MMTV-LUC and pTZ19 carrier plasmid as described above. After overnight incubation, dexamethasone (10 nM) was added, and luciferase activity was measured the next day. For the coexpression studies of TIF2 and AR.N1, the total amount of vector, added to each well, was equalized by the addition of empty vector, to a total concentration of 800 ng/well. In addition, pTZ19 carrier plasmid was added to a total concentration of 2 g DNA/well.
Yeast Growth and Methods
All yeast studies were performed in strain Y190 (MATa, ura3-52, his3-⌬200, ade2-101, trp1-901, leu2-3, leu2-112, GAL4⌬, GAL80⌬, URA3::GAL-lacZ, cyh r , LYS2::GAL-HIS3), which was purchased from CLONTECH. Yeast cells were grown in the appropriate selective minimal medium [0.67% (wt/vol) yeast nitrogen base without amino acids and 2% (wt/vol) dextrose, pH 5.8] supplemented to the nutritional requirements of the yeast transformants. Yeast transformations were carried out according to the lithium acetate method (38) .
Quantitative ␤-GAL activity assays, indicative of AR domain interactions, were performed as described previously (22) .
Immunoprecipitation and Immunoblotting
CHO cells were plated in 80-cm 2 culture flasks (1 ϫ 10 6 cells per flask), grown overnight, and transfected with 4 g ARplasmid and 16 g pTZ19 as carrier plasmid. The next day, medium was refreshed and the cells were grown for another day. Cytosol of the transfected cells was prepared as described before (22) . Immunoprecipitation was performed as described previously (39) , using monoclonal antibodies F112.1.1 [directed against synthetic peptide SP197; AR aa 1-20 (40) AR proteins in yeast were isolated as described previously (22) . Yeast-lysate samples (2.5 l) were run on SDSpolyacrylamide gels, after which the gels were electroblotted under semidry conditions. The blots were blocked overnight with 5% nonfat dry milk and incubated with GAL4AD monoclonal antibody (CLONTECH) or the polyclonal AR-antibody SP197. Proteins were visualized by chemiluminescence detection.
In Vivo Hormone Binding Assay
CHO cells were plated in six-well plates at a density of 1 ϫ 10 5 cells per well, grown overnight, and transfected as described above with AR-C or AR-C(EQ) (0.75 g/well). The whole-cell binding assay was performed 48 h later. Cells were washed once with PBS and incubated with various [ 3 H]R1881 (New England Nuclear) concentrations (0.01-30 nM) in the presence or absence of a 200-fold molar excess of unlabeled R1881 in DMEM/F12 for 1 h at 37 C. The cells were washed four times with PBS, collected in PBS, and transferred to a centrifuge tube. After centrifugation (10 min, 800 ϫ g) the pellet was lysed in 0.5 M NaOH (15 min at 56 C), and radioactivity was determined by liquid scintillation counting.
